Merrill: Confidence...
Health Care: Drugs
Halozyme Therapeutics Inc. (HALO: NASDAQ)
$7.59 0.02 | 0.26%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -53.55M | -19.77M | -53.24M | -58.36M |
| Operating Gains/Losses | 7.37K | -1.57K | 13.54K | 2.68K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -13.44M | 65.80K | 1.92M | 3.02M |
| (Increase) Decrease in Inventories | -2.10M | -373.84K | 966.13K | -718.23K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -3.26M | 711.78K | 3.44M | -2.00M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 3.01M | -17.04M | -2.70M | 10.92M |
| Other Non-Cash Items | 8.36M | 5.57M | 4.87M | 4.53M |
| Net Cash From Continuing Operations | -64.33M | -34.35M | -45.39M | -40.15M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -64.33M | -34.35M | -45.39M | -40.15M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.41M | -828.51K | -646.54K | -1.46M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.41M | -828.51K | -646.54K | -1.46M |
| Issuance of Debt | 29.66M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 83.16M | 4.75M | 61.82M | 45.36M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 112.82M | 4.75M | 61.82M | 45.36M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 47.08M | -30.43M | 15.79M | 3.75M |
Portfolios with HALO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserWatch
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- Contributor3 Stocks to Buy for Less Th...
- UserGFNN Stockdiagnostics 6
- ContributorStocks With Big Insider Buy...
- ContributorStocks At New 52-Week Highs...
Latest HALO Headlines from TheStreet
- Quick Take: The Next Big Thing in Biotech 05.17.13 | 10:05 am
- Biotech's Next Big Thing ASCO II
05.16.13 | 02:05 pm - 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Short Interest Increases 11.2% For HALO 05.10.13 | 03:05 pm
- 4 Under-$10 Stocks Making Big Moves 04.23.13 | 03:04 pm
- HALO Makes Bullish Cross Above Critical Moving Average 04.23.13 | 11:04 am
- 7 Stocks Under $10 Moving Higher 11.15.12 | 03:11 pm
- 5 Stocks With Big Insider Buying 08.29.12 | 11:08 am
- Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript 08.06.12 | 07:08 pm
- 5 Biotech Stocks Under $10 Set to Soar 07.19.12 | 11:07 am
Press Releases for HALO
- Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society Of Clinical Oncology Annual Meeting - PR Newswire 05.15.13 | 06:05 pm
- Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.07.13 | 04:05 pm
- Halozyme To Host First Quarter 2013 Financial Results Conference Call - PR Newswire 05.01.13 | 04:05 pm
- Halozyme Initiates Randomized Phase 2 Trial Of PEGPH20 In Pancreatic Cancer - PR Newswire 04.23.13 | 08:04 am
- Halozyme Therapeutics Names Matt Posard To Board Of Directors - PR Newswire 03.28.13 | 04:03 pm
- Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union - PR Newswire 03.22.13 | 08:03 am
- Halozyme Therapeutics To Present At The Barclays 2013 Global Healthcare Conference - PR Newswire 03.05.13 | 04:03 pm
- Halozyme To Host Fourth Quarter And 2012 Year-End Financial Results Conference Call - PR Newswire 02.19.13 | 04:02 pm
- Halozyme Therapeutics Issues Financial Guidance For 2013 - PR Newswire 01.07.13 | 07:01 am
- Halozyme Therapeutics To Present At The 31st Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.13 | 04:01 pm
Partner Headlines for HALO
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus - Benzinga 03.22.13 | 04:03 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- After Hours Most Active for Aug 1, 2012 : SAN, GMCR, NOK, FSLR, BBVA, SBUX, BAC, JNJ, LEN, HALO, QQQ, SPLS - NASDAQ 08.01.12 | 08:08 pm
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- Healthcare Biz Recap: GlaxoSmithKline BUYS Drugs, Sanofi Gains Traction - Wall St. Cheat Sheet 06.12.12 | 06:06 am
- Morning Market Losers - Benzinga 04.16.12 | 09:04 am
